BenevolentAI Atopic Dermatitis Drug Fails To Deliver

Trk Inhibitor Does Not Significantly Reduce Itch and Inflammation

05 Apr 2023

The UK artificial intelligence drug development expert has reported disappointing findings from a Phase II trial of lead candidate BEN-2293 in atopic dermatitis.

BenevolentAI Limited's approach of discovering and developing drugs using artificial intelligence has hit the buffers with the mid-stage failure of its lead drug for atopic dermatitis.

The UK-headquartered company has announced topline results from its Phase IIa study of BEN-2293, a topical pan-tropomyosin-related kinase (Trk) receptor...